
Drug Development Pharma - November 27, 2014
Lundbeck Alcohol Addiction Drug Wins Approval in UK
Just two days after the Danish company’s Lundbeck CEO stepped down for an ethics lapse, the UK’s National Institute for Health and Care Excellence (NICE) gave Selincro (namelfene) approval in final draft guidance, meaning the country’s National Health Service will make funding available for the £42.42-per-14-tablet-pack medication within three months. “We are pleased to be able […]